Payment overview · 2025
General Payments
$1,105.34
64 reported records · 23 companies
Healthcare provider profile · identity verified
Stephen Arthurs, MD
Allopathic & Osteopathic Physicians|Family Medicine · KINGFISHER, OK · NPI 1437190972
Verified facts
What the public records show
CMS Open Payments records show Stephen Arthurs, MD received $1,105.34 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Movantik, Ozempic, Trelegy Ellipta, Ubrelvy, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 380 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Gemtesa by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.80 | 12.6% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $122.25 | 11.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.11 | 7.0% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.84 | 6.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.76 | 6.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.71 | 6.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.81 | 5.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.16 | 5.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $51.32 | 4.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.20 | 4.5% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $45.19 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.78 | 3.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $38.16 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.10 | 3.4% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $25.23 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.52 | 2.1% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.48 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.98 | 1.6% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $16.95 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.70 | 1.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.45 | 1.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.25 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.59 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,105.34 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $122.25 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $89.98 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $77.11 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $74.84 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $73.76 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.61 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.61 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.19 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.16 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.81 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.81 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $55.16 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $51.32 | 3 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $45.19 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.52 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 380 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 65 | exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 295 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 146 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
380 | 79 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
146 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
295 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1753 | 226 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1185 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 703 | 201 |
| Oxycodone Hcl | Oxycodone Hcl | 623 | 67 |
| Lisinopril | Lisinopril | 462 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 105 |
| Celecoxib | Celecoxib | 418 | 122 |
| Farxiga | Dapagliflozin Propanediol | 380 | 79 |
| Trazodone Hcl | Trazodone Hcl | 350 | 63 |
| Metformin Hcl | Metformin Hcl | 344 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 325 | 84 |
| Gabapentin | Gabapentin | 322 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 74 |
| Ozempic | Semaglutide | 295 | 43 |
| Morphine Sulfate Er | Morphine Sulfate | 222 | 44 |
| Enalapril Maleate | Enalapril Maleate | 210 | 46 |
| Mounjaro | Tirzepatide | 204 | 30 |
| Furosemide | Furosemide | 197 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 55 |
| Eliquis | Apixaban | 178 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 41 |
| Carvedilol | Carvedilol | 176 | 39 |
| Omeprazole | Omeprazole | 163 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 27 |
| Simvastatin | Simvastatin | 146 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 146 | 31 |
| Buprenorphine Hcl | Buprenorphine Hcl | 143 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 32 |
| Losartan Potassium | Losartan Potassium | 127 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 125 | 26 |
| Potassium Chloride | Potassium Chloride | 119 | 27 |
| Azithromycin | Azithromycin | 116 | 97 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 21 |
| Allopurinol | Allopurinol | 109 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 33 |
| Famotidine | Famotidine | 102 | 16 |
| Ibuprofen | Ibuprofen | 97 | 17 |
| Buspirone Hcl | Buspirone Hcl | 89 | 27 |
| Montelukast Sodium | Montelukast Sodium | 86 | 22 |
| Chlorthalidone | Chlorthalidone | 83 | 27 |
| Hydromorphone Hcl | Hydromorphone Hcl | 83 | 23 |
| Meloxicam | Meloxicam | 82 | 24 |
| Pregabalin | Pregabalin | 82 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 12 |
| Ezetimibe | Ezetimibe | 68 | 14 |
| Naloxone Hcl | Naloxone Hcl | 67 | 65 |
| Prednisone | Prednisone | 67 | 29 |
| Tramadol Hcl | Tramadol Hcl | 67 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Gemtesa | Vibegron | 65 | 15 |
| Cephalexin | Cephalexin | 60 | 46 |
| Meclizine Hcl | Meclizine Hcl | 59 | 18 |
| Oxycontin | Oxycodone Hcl | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 14 |
| Ondansetron Odt | Ondansetron | 53 | 16 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Xtampza Er | Oxycodone Myristate | 50 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 16 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Movantik | Naloxegol Oxalate | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | 11 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 32 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 12 |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Etodolac | Etodolac | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 25 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Topiramate | Topiramate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Atenolol | Atenolol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Linzess | Linaclotide | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 20 |
| Diazepam | Diazepam | 20 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Neurontin | Gabapentin | 11 | suppressed |
| Nourianz | Istradefylline | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,105.34 · 64 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, Auvelity, FANAPT, FARXIGA, GEMTESA, GVOKE HYPOPEN, Kerendia, LOREEV XR, MOVANTIK, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIA MATRIX, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error